Project 2: Multiple Antigen-Engineered DC Immunization and IFNa Boost for Metastatic Melanoma This application will build on progress made in our previous tumor antigen targeting trials to test a new genetically engineered dendritic cell-based vaccine regimen designed to more potently activate CDS and CD4 T cells specific to multiple melanoma antigens. We will couple this vaccine trial with thorough immunological monitoring to study T cell responses to the vaccine and the importance of determinant spreading for clinical response. We hypothesize that vaccination with multiple full length tumor antigens will activate a broad range of CD4 and CDS T cells, and that in the subset of patients who further activate and diversify their T cell response to include other antigens expressed by their tumor (or undergo """"""""determinant spreading""""""""), objective clinical response will be observed. We also hypothesize that systemic IFNa delivered after the vaccine will boost the vaccine-specific T cell responses. A.
Specific Aims : A.1. Conduct an Antigen-Engineered DC Trial with an IFNa Boost. We will treat 30 subjects with antigen engineered DC and randomize half to receive an IFNa boost. A.2.Assess the Biology of the CDS and CD4 Immune Responses to Immunizing Antigens MART-1, Tyrosinase and MAGE-A6. We will follow CDS and CD4 T cell responses to the three immunizing antigens, as well as the adenovirus vector. We will also investigate TIL responses to the immunizing antigens and tumor antigen expression in accessible tumor deposits. A.3. Assess Determinant Spreading. We will also follow the CDS and CD4 T cell responses to defined melanoma-associated antigens not included in the vaccine but commonly expressed by tumors (including gplOO) and uncharacterized antigens expressed by autologous tumor to determine the importance of determinant spreading to objective clinical response.
|Anderson, Alyce; Ferris, Laura K; Click, Benjamin et al. (2018) Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci 63:2729-2739|
|Zhang, Yi; Liu, Zuqiang; Hao, Xingxing et al. (2018) Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model. Cancer Immunol Immunother 67:353-366|
|Lemchak, David; Banerjee, Swati; Digambar, Shaunak S et al. (2018) Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol 27:188-190|
|Matsumoto, Martha; Secrest, Aaron; Anderson, Alyce et al. (2018) Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol 78:701-709.e1|
|Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054|
|Santos, Patricia M; Butterfield, Lisa H (2018) Dendritic Cell-Based Cancer Vaccines. J Immunol 200:443-449|
|Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :|
|Retseck, Janet; Nasr, Alexis; Lin, Yan et al. (2018) Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. J Transl Med 16:184|
|Velásquez, Celestino; Amako, Yutaka; Harold, Alexis et al. (2018) Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1. Front Microbiol 9:713|
|Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15|
Showing the most recent 10 out of 209 publications